The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The production suspension impacts commercial and clinical trial supply
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Subscribe To Our Newsletter & Stay Updated
